Anus cancer
Drug research and approvals for anus cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 85 studies of anus cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 85
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- A Study of Retifanlimab After Chemoradiation in People With Anal CancerNCT07927998 · Phase 2 · Memorial Sloan Kettering Cancer Center · starts Nov 4, 2026
- Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)NCT07782164 · Not reported · Amsterdam UMC, location VUmc · starts Apr 18, 2025
- Evaluation of the Ileo-anal Pouch in FAP (ENDOPOL)NCT07726771 · Not applicable · London North West Healthcare NHS Trust · starts Jul 9, 2026
- Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell CarcinomaNCT07692152 · Phase 3 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · starts Mar 17, 2026
- A Study of IDP-001 in Advanced or Metastatic Solid TumorsNCT07602842 · Phase 1 / Phase 2 · InduPro, Inc. · starts Jul 8, 2026
- Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer:ChaseNCT07555678 · Phase 2 · Fudan University · starts Apr 1, 2024
- Towards an Understanding of Barriers and Delays in the Diagnosis of Anal CancerNCT07455942 · Not reported · Centre Hospitalier Intercommunal Creteil · starts Jun 23, 2026
- Concordance and Acceptability of Self-screening Compared to Screening Carried Out by a Health Professional for HPV, a…NCT07438080 · Not applicable · Centre Hospitalier Universitaire de la Réunion · starts Apr 9, 2025
- ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal CancerNCT07425054 · Phase 2 · Jennifer Dorth · starts Jun 19, 2026
Phase 3 4
- MitomycinDNA inhibitor
- FluorouracilThymidylate synthase inhibitor
- CisplatinDNA inhibitor
- CidofovirHuman herpesvirus 1 DNA polymerase inhibitor
Phase 2 8
- CapecitabineThymidylate synthase inhibitor
- CetuximabEpidermal growth factor receptor erbB1 inhibitor
- OxaliplatinDNA inhibitor
- PembrolizumabProgrammed cell death protein 1 inhibitor
- AtezolizumabProgrammed cell death 1 ligand 1 inhibitor
- DurvalumabProgrammed cell death 1 ligand 1 inhibitor
- Indigo
- Bizalimogene ralaplasmid
Phase 1 or earlier 12
- CarboplatinDNA inhibitor
- IrinotecanDNA topoisomerase I inhibitor
- PaclitaxelTubulin inhibitor
- RitonavirHuman immunodeficiency virus type 1 protease inhibitor
- TrastuzumabReceptor protein-tyrosine kinase erbB-2 inhibitor
- VorinostatHistone deacetylase 1 inhibitor
- LopinavirHuman immunodeficiency virus type 1 protease inhibitor
- UCN-01Cyclin-dependent kinase 2 inhibitor
- Verpasep caltespenChaperonin GroEL 2 vaccine antigen
- Edodekin alfa
- Tempol
- Pexipepimut-sAnal gland cancer
How its trials ended
239 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 50 whose ending is known, 30% met their primary endpoint, 8% missed it and 62% stopped early.
- Ongoing9238%
- Completed, result not reported7431%
- Status unknown2310%
- Met its primary endpoint156%
- Stopped: other or unclear146%
- Stopped: enrollment or feasibility94%
- Stopped: lack of efficacy52%
- Missed its primary endpoint42%
- Stopped: safety21%
- Stopped: sponsor or business decision1<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA